Satellos Bioscience Inc. (TSX:MSCL)
Canada · Delayed Price · Currency is CAD 13.95
+0.26 (1.90%)
Jul 24, 2026, 3:55 PM EST
Satellos Bioscience Employees
As of December 31, 2025, Satellos Bioscience had 21 total employees, including 18 full-time and 3 part-time employees. The number of employees increased by 4 or 23.53% compared to the previous year.
Employees
21
Change (1Y)
4
Growth (1Y)
23.53%
Revenue / Employee
n/a
Profits / Employee
-1.99M CAD
Market Cap
290.60M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 21 | 4 | 23.53% | 18 | 3 |
| Dec 31, 2024 | 17 | 1 | 6.25% | 14 | 3 |
| Dec 31, 2023 | 16 | - | - | 4 | 12 |
Related Stocks
| Company Name | Employees |
|---|---|
| Eupraxia Pharmaceuticals | 49 |
| Bright Minds Biosciences | 26 |
| BriaCell Therapeutics | 16 |
| Sernova Biotherapeutics | 8 |
| Helix BioPharma | 7 |
Satellos Bioscience News
- 15 days ago - Satellos Bioscience DMD Drug Shows Early Promise in 6-Month Study Update - MarketBeat
- 17 days ago - Satellos Bioscience Inc TRAILHEAD Study Data Update Call Transcript - GuruFocus
- 18 days ago - Satellos Bioscience Transcript: Study update - Transcripts
- 18 days ago - Satellos Bioscience Press release: Study update - Filings
- 18 days ago - Satellos Bioscience Slides: Study update - Filings
- 18 days ago - Satellos Reports Six-Month Interim TRAILHEAD Data Showing Reduced Muscle Fat Fraction, Increased Effort, Stable Strength, Lower CK and Favorable Safety Profile in DMD Adults Treated with SAT-3247 - GlobeNewsWire
- 19 days ago - Satellos Bioscience Slides: Corporate presentation - Filings
- 26 days ago - Satellos' SAT-3247 Wins FDA Fast Track Status For Duchenne Muscular Dystrophy, Stock Up - Nasdaq